Moreover, in vivo results indicated that FV-429 inactivated c-Src/Stat3/HIF-1α pathway in hypoxic tumor tissues (Figures 6d and e) and FV-429, combined with paclitaxel, induced significant increased G2/M-specific protein expression in tumor tissues (Figures 6b and c) with an inhibition rate of 57.5%, confirming the effectiveness of FV-429 in improving paclitaxel treatment by G2/M phase arrest enhancement through c-Src/Stat3/HIF-1α pathway in vivo. This evidence concerns the gene SRC and neoplasm.